Free Trial
NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx logo
$1.22 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.41%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About RenovoRx Stock (NASDAQ:RNXT)

Key Stats

Today's Range
$1.18
$1.26
50-Day Range
$0.77
$1.24
52-Week Range
$0.75
$1.69
Volume
196,895 shs
Average Volume
85,147 shs
Market Capitalization
$44.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

RNXT MarketRank™: 

RenovoRx scored higher than 53% of companies evaluated by MarketBeat, and ranked 477th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RenovoRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about RenovoRx's stock forecast and price target.
  • Earnings Growth

    Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RenovoRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RenovoRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.72% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    RenovoRx does not currently pay a dividend.

  • Dividend Growth

    RenovoRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.72% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    RenovoRx has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for RenovoRx this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,218.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 9.13% of the stock of RenovoRx is held by insiders.

  • Percentage Held by Institutions

    Only 3.10% of the stock of RenovoRx is held by institutions.

  • Read more about RenovoRx's insider trading history.
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Stock News Headlines

RenovoRx's (RNXT) "Buy" Rating Reaffirmed at HC Wainwright
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

RNXT Stock Analysis - Frequently Asked Questions

RenovoRx's stock was trading at $1.29 at the start of the year. Since then, RNXT shares have decreased by 5.4% and is now trading at $1.22.
View the best growth stocks for 2025 here
.

RenovoRx, Inc. (NASDAQ:RNXT) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The company earned $0.20 million during the quarter, compared to analyst estimates of $0.23 million.
Read the conference call transcript
.

RenovoRx (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

Top institutional shareholders of RenovoRx include AIGH Capital Management LLC (9.49%), AWM Investment Company Inc. (6.25%), Alyeska Investment Group L.P. (1.88%) and ADAR1 Capital Management LLC (1.31%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms.
View institutional ownership trends
.

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

Last Earnings
5/15/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNXT
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$11.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+473.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$240,000.00
Price / Cash Flow
N/A
Book Value
($0.28) per share
Price / Book
-4.36

Miscellaneous

Free Float
22,297,000
Market Cap
$44.62 million
Optionable
Not Optionable
Beta
1.12
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:RNXT) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners